FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310106521> ?p ?o ?g. }

• W4310106521 endingPage "9990" @default.
• W4310106521 startingPage "9989" @default.
• W4310106521 abstract "The monoclonal antibody (mAb) daratumumab (DARA) targeting CD38 can induce minimal residual disease negative remissions in patients with multiple myeloma (MM). However, majority of patients subsequently relapse or become refractory to treatment (RRMM). Rapid reduction of surface CD38 levels in MM cells following DARA infusion due to trogocytosis by monocytes and granulocytes leads to reduced complement dependent cytotoxicity (CDC) and antibody dependent cellular cytotoxicity (ADCC), effector functions that rely on antigen density. High expression of complement regulatory proteins, CD55 and CD59 on MM cell surface can also impede CDC activity. Therefore, modalities to overcome these limitations and improve clinical outcome for patients with RRMM are needed. Daratumumab is a strong activator of complement. While a subset of cells may be lysed by the membrane attack complex, all cells reacted with daratumumab are opsonized by C3d, the terminal component of C3. C3d remains covalently attached at the cell surface. Thus, the newly acquired membrane bound C3d constitutes a target for additional intervention, particularly when the cell surface CD38 is lost or low following treatment with DARA. Using phage display technology, we generated and characterized recombinant rabbit/human chimeric mAbs that selectively bind C3 fragments including C3d but not full length C3. We selected two high affinity anti-C3d mAbs (clones 5S8 and d301 with kD values 3.35 nM and 0.99 nM, respectively) that showed reactivity against both human and mouse C3d. To deposit C3d on myeloma cell lines (MM1-S, MM1-R, RPMI8226, NCI-H929, KMS-12-PE) without activating CDC, the cells were reacted with DARA in C5 depleted normal human serum. Both 5S8 and d301 bound to the C3d opsonized cells. Based on SPR analysis these two mAbs do not compete for C3d binding suggesting that they recognize distinct epitopes. In normal human serum, the anti-C3d mAbs enhanced killing by CDC of DARA-opsonized target cells compared to DARA alone (P<0.0001). The non-targeting IgG1 isotype control mAb trastuzumab (TRA) did not bind C3d or enhance DARA-mediated killing. To test the combination of DARA with anti-C3d mAbs in vivo, we used Balb/c-SCID mice bearing subcutaneous (s. c.) MM1-R tumors. First, using clones 5S8 and d301, we demonstrated in vivo binding of mouse C3d on MM1-R tumor cells harvested 24 h after a single intraperitoneal (i. p.) injection of DARA. Next, we challenged the mice s. c. with MM1-R cells and randomly divided them into the following treatment groups: 20 mg/kg DARA single agent (n=7), or combination treatments of 10 mg/kg of each of two mAbs: DARA + TRA (n=10), DARA + 5S8 (n=13), DARA + d301 (n=13). The mAbs were given via i. p. injections weekly starting on day 7 post tumor challenge and continued for 6 weeks. Palpable tumors were noticed in mice between days 7 and 14, and tumor growth was monitored by caliper measurements twice weekly. Mice were euthanized when tumors reached pre-defined limits. All the mice that received DARA + TRA showed progressive tumor growth with median survival of 38 days and all mice had to be euthanized by day 50. Doubling the dose of DARA to 20mg/kg slightly increased median survival to 43 days (P = 0.12 vs DARA+TRA). Two of 7 mice that received DARA alone (at 20 mg/kg) survived to day 175. Median survival for mice treated with DARA (10mg/kg) plus an anti-C3d mAb was 162 days (P = 0.006 for comparison to DARA 20mg/kg), and 13 of 26 (50%) mice in this cohort survived tumor-free beyond 200 days. There was no statistically significant difference between groups treated with 5S8 or d301 in combination with DARA (P = 0.23). All the surviving mice showed no evidence of tumor, weight loss or other morbidity indicating that they are essentially tumor-free. In summary, these results demonstrate that combination treatment of DARA with anti-C3d mAbs improves efficacy over single agent DARA leading to long-term survival in the MM.1R xenograft model. The combination of C3d targeting mAbs with DARA could improve clinical efficacy and overcome resistance to single agent therapy." @default.
• W4310106521 created "2022-11-30" @default.
• W4310106521 creator A5030524385 @default.
• W4310106521 creator A5044521397 @default.
• W4310106521 creator A5065812703 @default.
• W4310106521 creator A5088287990 @default.
• W4310106521 date "2022-11-15" @default.
• W4310106521 modified "2023-10-01" @default.
• W4310106521 title "<i>Targeting C3d in Combination with Daratumumab:</i> <i>a Strategy to Enhance Therapeutic Potential in Multiple Myeloma</i>" @default.
• W4310106521 doi "https://doi.org/10.1182/blood-2022-166681" @default.
• W4310106521 hasPublicationYear "2022" @default.
• W4310106521 type Work @default.
• W4310106521 citedByCount "0" @default.
• W4310106521 crossrefType "journal-article" @default.
• W4310106521 hasAuthorship W4310106521A5030524385 @default.
• W4310106521 hasAuthorship W4310106521A5044521397 @default.
• W4310106521 hasAuthorship W4310106521A5065812703 @default.
• W4310106521 hasAuthorship W4310106521A5088287990 @default.
• W4310106521 hasBestOaLocation W43101065211 @default.
• W4310106521 hasConcept C126322002 @default.
• W4310106521 hasConcept C143998085 @default.
• W4310106521 hasConcept C2776063141 @default.
• W4310106521 hasConcept C2776364478 @default.
• W4310106521 hasConcept C2777478702 @default.
• W4310106521 hasConcept C2778524551 @default.
• W4310106521 hasConcept C2780108899 @default.
• W4310106521 hasConcept C2781098529 @default.
• W4310106521 hasConcept C2781119759 @default.
• W4310106521 hasConcept C502942594 @default.
• W4310106521 hasConcept C71924100 @default.
• W4310106521 hasConcept C98274493 @default.
• W4310106521 hasConceptScore W4310106521C126322002 @default.
• W4310106521 hasConceptScore W4310106521C143998085 @default.
• W4310106521 hasConceptScore W4310106521C2776063141 @default.
• W4310106521 hasConceptScore W4310106521C2776364478 @default.
• W4310106521 hasConceptScore W4310106521C2777478702 @default.
• W4310106521 hasConceptScore W4310106521C2778524551 @default.
• W4310106521 hasConceptScore W4310106521C2780108899 @default.
• W4310106521 hasConceptScore W4310106521C2781098529 @default.
• W4310106521 hasConceptScore W4310106521C2781119759 @default.
• W4310106521 hasConceptScore W4310106521C502942594 @default.
• W4310106521 hasConceptScore W4310106521C71924100 @default.
• W4310106521 hasConceptScore W4310106521C98274493 @default.
• W4310106521 hasIssue "Supplement 1" @default.
• W4310106521 hasLocation W43101065211 @default.
• W4310106521 hasOpenAccess W4310106521 @default.
• W4310106521 hasPrimaryLocation W43101065211 @default.
• W4310106521 hasRelatedWork W2016202982 @default.
• W4310106521 hasRelatedWork W2478188943 @default.
• W4310106521 hasRelatedWork W2549893547 @default.
• W4310106521 hasRelatedWork W2615497162 @default.
• W4310106521 hasRelatedWork W2731606591 @default.
• W4310106521 hasRelatedWork W2734396891 @default.
• W4310106521 hasRelatedWork W2920340622 @default.
• W4310106521 hasRelatedWork W2939294425 @default.
• W4310106521 hasRelatedWork W2995945119 @default.
• W4310106521 hasRelatedWork W3114717300 @default.
• W4310106521 hasVolume "140" @default.
• W4310106521 isParatext "false" @default.
• W4310106521 isRetracted "false" @default.
• W4310106521 workType "article" @default.